

8–9 December 2022

SCANPROST Meeting

Malmö Live Clarion Hotel
Malmö, Sweden

A Scandinavian meeting to discuss recent
developments in prostate cancer

During recent years we have seen an accelerating pace in the development and adoption of new techniques in diagnosis and treatment of prostate cancer. This has led to earlier treatment, improved outcomes, and longer life for many patients. It is therefore our great pleasure to invite you to this year's SCANPROST meeting to discuss and assess some of these recent developments.

Professor Anders Bjartell has prepared the movie below explaining more details of the event:



CP-349620 10/2022

Registration

SCANPROST Meeting

(Malmö Live Clarion Hotel - Malmö, Sweden)

Date: 8–9 December 2022

Time: 12.30 (Thursday December 8th) – 11.30 (Friday December 9th)

Last registration date: November 25th

[Click here to register](#)

On behalf of the SCANPROST Scientific Steering Committee:



Anders Bjartell, Professor, Urological cancer, Malmö and Division of Translational Cancer Research, Lund university, Sweden.



Michael Borre, Professor, Department of Clinical Medicine and Department of Urology, Aarhus University, Denmark.



Henrik Grönberg, Professor, Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm and Capio St: Görans Hospital, Sweden.

Agenda

Thursday December 8th

12.30	Arrival and lunch	
13.00	Welcome	Anders Bjartell (Sweden)
13.15	Active surveillance:	Chair: Michael Borre (Denmark)
	<ul style="list-style-type: none"> How to monitor active surveillance? Should we use MRI and how to do it? Problems with active surveillance, should we really offer it to everyone? Discussion and question 	Anna Bill-Axelsson (Sweden) Fredrik Jäderling (Sweden) Marcus Graefen (Germany)
14.30	PSMA-PET in primary staging:	Chair: Anders Bjartell (Sweden)
	<ul style="list-style-type: none"> Pros Cons Discussion and questions 	Stefano Fanti (Italy) Andreas Røder (Denmark)
15.15	Coffee Break	
15.30	Should all men have triplet therapy in mHSPC?	Chair: Henrik Grönberg (Sweden)
	<ul style="list-style-type: none"> Pros Cons Is there still room for RT in the era of intensified treatment of mHSPC? Discussion and question 	Laura-Maria Krabbe (Germany) Noel Clarke (England) Philip Cornford (England)
16.30	End Day 1	
18.30	Dinner	

Friday December 9th

09.00	Radioligand therapy as SoC in mCRPC:	Chair: Anders Bjartell (Sweden)
	<ul style="list-style-type: none"> Pros Cons Discussion and questions 	Tobias Maurer (Germany) Stefano Fanti (Italy)
10.00	Coffee Break	Anders Bjartell (Sweden)
10.15	Precision medicine in mCRPC – when to test and how to test? What material?	Chair: Henrik Grönberg (Sweden)
	<ul style="list-style-type: none"> Pitfalls of genetic testing Who and when to test? Discussion and questions 	Johan Lindberg (Sweden) Noel Clarke (England)
11.00	Wrap-up	Michael Borre (Denmark)
11.30	End Day 2 and lunch	

The Scientific Steering Committee has been responsible for the development of the program and scientific content of Day 1 and Day 2.

Additional speakers



Anna Bill-Axelsson, Professor of Urology, Department of Surgical Sciences, Uppsala University, Sweden.



Noel Clarke, Consultant Urological Surgeon, Professor of Urological Oncology, The Christie Hospital Manchester, England.



Philip Cornford, Associate clinical Professor Department of Urology, Liverpool University Hospitals, England.



Stefano Fanti, Professor, Diagnostic Imaging, University of Bologna, Italy.



Marcus Graefen, Professor of Urology & Chairman of Martini-Klinik, Prostate Cancer Center at the University Medical Center Hamburg-Eppendorf, Germany.



Fredrik Jäderling, PhD, Radiologist, Department of Molecular Medicine and Surgery (MMK), Karolinska Institutet, and Dept. of Radiology Capio St: Görans Hospital, Sweden.




Laura-Maria Krabbe, Professor, Department of Urology, The University of Muenster Medical Center, Germany.



Johan Lindberg, Senior Researcher, Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Sweden.



Tobias Maurer, Professor, Faculty Martini-Klinik and Department of Urology, University of Hamburg-Eppendorf, Germany.



Andreas Røder, Professor, Department of Urology and Copenhagen Prostate Cancer Center, Rigshospitalet, Denmark.

Additional information

This meeting is free of charge for its participants as Janssen finances this meeting. According to the agreement between LIF and SKR, pharmaceutical companies may not cover the cost of either travel or accommodation. For this reason, each participant is responsible for booking and paying its own travel and accommodation. Remember: the participant is responsible for the employer's approval to participate in the meeting.

For questions regarding registration, contact:

Karin Ekenberg, Business Operations Specialist Janssen

Email: kekenber@its.jnj.com

Phone: +46 73 665 39 84

For questions regarding the event, contact:

Anna Sandqvist, PhD, Medical Advisor Janssen

Email: asandqv1@its.jnj.com

Phone: +46 72 545 24 23

Welcome!

Kind regards

Janssen Academy on behalf of the Scientific Steering Committee.

Medicinsk Information

jacse@its.jnj.com

janssen.com/sweden

Janssen-Cilag AB, Box 4042, SE-16904 Solna, Sweden

+ 46 8 626 50 00

+ 46 8 626 51 00

CP-349796 10/2022